HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Previous close
$2.32
Day range
$2.15 - $2.32
Year range
$0.97 - $9.79
Market cap
12.48M USD
Avg Volume
157.05K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.24M | 17.84% |
Net income | -2.17M | -17.33% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -2.31M | -20.67% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 10.78M | 129.35% |
Total assets | 11.30M | 113.39% |
Total liabilities | 1.21M | -20.81% |
Total equity | 10.10M | — |
Shares outstanding | 5.73M | — |
Price to book | 1.10 | — |
Return on assets | -46.66% | — |
Return on capital | -51.85% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -2.17M | -17.33% |
Cash from operations | -2.54M | -42.94% |
Cash from investing | -3.00K | — |
Cash from financing | 40.00K | — |
Net change in cash | -2.50M | -40.86% |
Free cash flow | -1.82M | -61.47% |
About
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Founded
2011
Website
Employees
5
